Saturday, January 16th, 2021

FDA Issues Recommendation to DEA to Change Marijuana’s Classification from a Schedule 1 Drug

Published on December 27, 2015 by   ·   No Comments


Jay Syrmopoulos

recently revealed document indicates that top federal health officials have given the Drug Enforcement Agency (DEA) a recommendation to reschedule marijuana under the federal Controlled Substances Act. However, the details of that recommendation are not entirely clear.

Cannabis is currently considered a Schedule 1 drug under federal law, a classification reserved for drugs considered to have no medical value. So, if any rescheduling is to happen, it can only get better.

According to the document obtained by

“DEA recently received the [Department of Health and Human Services] scientific and medical evaluations as well as a scheduling recommendation that HHS prepared in response to” two petitions to reschedule cannabis under the federal Controlled Substances Act, Assistant Attorney General Peter J. Kadzik wrote in a September 30 letter to Rep. Earl Blumenauer (D-OR). “DEA is currently reviewing these documents and all other relevant data to make a scheduling determination in accordance with the [Controlled Substances Act].”

The most recent DEA denial of a cannabis rescheduling petition came in 2011, almost five years after the FDA’s input was forwarded in December of 2006. Prior to that denial, a petition to reschedule was denied in March of 2001, only two months after the FDA recommendation was made.

One of the petitions referenced was filed in 2011 by former Washington State Governor Christine Gregoire; with the other being filed by former Rhode Island Governor Lincoln Chafee.

Referencing the most recent petitions to reschedule cannabis, Asst. Attorney General Kadzik in his correspondence wrote that, “Upon completion of the determination, DEA will notify the petitioners of its decision and plans to publish the full analyses of both HHS and DEA in the Federal Register.”

HHS, in accordance with federal law, is required to weigh numerous factors when making a recommendation to the DEA, including physical and psychological dependence, potential for abuse, evidence of the drugs pharmacological effects and risk to public health.

Kadzick’s letter to Blumenauer makes clear that as of September 30, 2015 the DEA had received a rescheduling recommendation from the FDA.

Read More HERE

Share the Truth:
  • Digg
  • Facebook
  • Twitter
  • Google Bookmarks
  • Global Grind
  • MySpace
  • Tumblr
  • email

Readers Comments (0)

Please note: Comment moderation is enabled and may delay your comment. There is no need to resubmit your comment.

Daily News and Blogs

Listen to the TIS Network on

Check Out Pop Culture Podcasts at Blog Talk Radio with TIS Network on BlogTalkRadio

Like us on Facebook

Advertise Here

Advertise Here